PRESS RELEASE
31 October 2024

Appleby Bermuda Advised Organon On Acquisition Of Dermavant

A
Appleby

Contributor

Appleby is one of the world’s leading offshore law firms, operating in 10 highly regarded and well-regulated locations. We provide comprehensive, expert advice and services across a number of key practice areas. We work with our clients to achieve practical solutions whether from a single location or across multiple jurisdictions.
Appleby Bermuda advised Organon & Co on the acquisition, by way of merger under Bermuda law, of Dermavant Sciences Ltd. Organon (NYSE: OGN) is a global healthcare company with a mission to improve the health of women.
Bermuda

Appleby Bermuda advised Organon & Co on the acquisition, by way of merger under Bermuda law, of Dermavant Sciences Ltd. Organon (NYSE: OGN) is a global healthcare company with a mission to improve the health of women. Dermavant is dedicated to developing and commercialising innovative therapeutics in immuno-dermatology.

The Appleby Bermuda team was led by Partner Sally Penrose and included Senior Associate Katie Blundy, Associate Ojeda Smith and Trainee Mya Gibbons.

As a leading offshore corporate law firm, our team of corporate solicitors and lawyers specialise in providing comprehensive legal solutions for businesses and organisations of all shapes and sizes.

Our experienced offshore corporate lawyers offer a wide range of advice in corporate and commercial law, with particular expertise and focus on financing transactions, mergers and acquisitions, corporate restructurings, capital markets, joint ventures, fintech, insurance and investment funds.

Contributor

Appleby is one of the world’s leading offshore law firms, operating in 10 highly regarded and well-regulated locations. We provide comprehensive, expert advice and services across a number of key practice areas. We work with our clients to achieve practical solutions whether from a single location or across multiple jurisdictions.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More